
Protalix BioTherapeutics, Inc.
AMEX:PLX
1.44 (USD) • At close November 27, 2023
Overzicht | Financiële gegevens
Bedrijfsnaam | Protalix BioTherapeutics, Inc. |
Symbool | PLX |
Munteenheid | USD |
Prijs | 1.4 |
Beurswaarde | 100,213,120 |
Dividendpercentage | 0% |
52-weken bereik | 1.03 - 3.55 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Dror Bashan |
Website | https://www.protalix.com |
An error occurred while fetching data.
Over Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)